Free Trial

Singular Genomics Systems Q4 2022 Earnings Report

Singular Genomics Systems logo
$19.60 +0.17 (+0.87%)
(As of 05:21 PM ET)

Singular Genomics Systems EPS Results

Actual EPS
-$8.70
Consensus EPS
-$11.10
Beat/Miss
Beat by +$2.40
One Year Ago EPS
N/A

Singular Genomics Systems Revenue Results

Actual Revenue
$0.77 million
Expected Revenue
$0.60 million
Beat/Miss
Beat by +$170.00 thousand
YoY Revenue Growth
N/A

Singular Genomics Systems Announcement Details

Quarter
Q4 2022
Time
N/A

Conference Call Resources

We recommended Palantir in 2021, now we’re recommending this... (Ad)

My research indicates there is only one investment that can meet AI's unprecedented demand for energy.

Click to get the name and ticker symbol
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Singular Genomics Systems? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Singular Genomics Systems and other key companies, straight to your email.

About Singular Genomics Systems

Singular Genomics Systems (NASDAQ:OMIC), a life science technology company, develops next generation sequencing and multiomics technology for researchers and clinicians to advance science and medicine. The company is involved in the developing of G4, consisting of G4 instrument and associated consumables for various applications, such as max read kits for single cell sequencing, rare variant detection with high-definition sequencing, gene fusion detection with ring-seq, and extended range sequencing; and PX instrument and associated consumables for applications comprising single cell gene expression and proteomics, in situ RNA sequencing, and spatial RNA and proteomics applications for tissue. Singular Genomics Systems, Inc. was incorporated in 2016 and is based in San Diego, California.

View Singular Genomics Systems Profile

More Earnings Resources from MarketBeat